Financial Performance - The company achieved a net profit attributable to shareholders of the parent company of RMB 171,180,295.61 for the year 2024[6]. - The profit available for distribution to shareholders amounted to RMB 424,808,898.77[6]. - The proposed cash dividend is RMB 0.784 per 10 shares (including tax) based on the total share capital on the dividend distribution date[6]. - The company's operating revenue for 2024 reached ¥271,039,818.26, representing a 12.59% increase compared to ¥240,722,981.59 in 2023[23]. - Net profit attributable to shareholders for 2024 was ¥171,180,295.61, a significant increase of 172.28% from ¥62,870,202.71 in 2023[23]. - The net cash flow from operating activities improved to ¥46,473,090.72 in 2024, compared to a negative cash flow of -¥8,367,280.38 in 2023[23]. - The company's total assets increased by 10.20% to ¥1,826,839,219.54 at the end of 2024, up from ¥1,657,749,783.34 at the end of 2023[23]. - Basic earnings per share rose to ¥0.27 in 2024, reflecting a 170.00% increase from ¥0.10 in 2023[24]. - The weighted average return on equity increased to 12.91% in 2024, up by 7.59 percentage points from 5.32% in 2023[24]. - The company reported a decrease in net profit after deducting non-recurring items, which fell by 10.49% compared to the previous year[25]. Strategic Developments - The company completed a major asset restructuring, acquiring 55% of Ruisheng Bio and selling 30% of Cayman WuXi AppTec, which contributed to the profit increase[24]. - The acquisition of 55% equity in Ruisheng Bio contributed a net profit of 138.17 million yuan, exceeding the performance commitment of 125 million yuan for 2024[32]. - The company sold a 30% stake in Cayman WuXi AppTec, generating an investment return exceeding 100 million yuan, enhancing liquidity and risk resistance[34]. - The divestment of 76.07% equity in Yangling Jinhai, which had been in a loss-making state, improved the company's profitability and significantly reduced the asset-liability ratio[34]. - The company plans to continue expanding its market presence and investing in new product development as part of its growth strategy[24]. Market Insights - The IVD industry is projected to grow at an annual rate of 5%-7%, with the global market expected to exceed 100 billion USD in 2024[38]. - The domestic market for biochemical diagnostic reagents and immunodiagnostic reagents accounts for 60% of the IVD market share, with local manufacturers achieving international technical standards[38]. - The market for oral bone repair materials is expected to grow at a compound annual growth rate of 30.77%, reaching 3.5 billion yuan by 2028[39]. - The medical device industry, where the company operates, has a global market size of approximately $500 billion, with a growth rate of 7%-10% annually[75]. - The global market size for regenerative medicine in oral tissue repair and regeneration has exceeded $5 billion in 2023, with a compound annual growth rate of approximately 9%[77]. Research and Development - The company has strengthened internal control systems and improved the compliance awareness of key personnel through training and supervision[36]. - The company is investing in R&D and collaborating with Japanese research institutions to enhance production efficiency and reduce reliance on imported raw materials[35]. - The company has established a complete R&D management system, enabling it to independently develop new technologies and products in the field of oral repair materials[43]. - The company has a strong R&D team with 22 personnel, including 11 with master's degrees and 12 with over 10 years of experience, enhancing its innovation capabilities[48]. - Key R&D projects include the development of various diagnostic kits, currently in the pilot production stage, aimed at detecting specific biomarkers in human serum[81]. Corporate Governance - The company has established a strict insider information registration system, with the chairman as the main responsible person and the board secretary managing the registration process[119]. - The company plans to further improve its corporate governance structure and enhance risk control measures by 2025[119]. - The company emphasizes the importance of internal control and management efficiency post-acquisition of Ruisheng Bio[98]. - The company has established specialized committees under the board, including an audit committee and a strategic committee[139]. - The company is committed to maintaining transparency and accountability in its governance practices following the board elections[129]. Environmental and Social Responsibility - The company invested 221,800 RMB in environmental protection during the reporting period[169]. - The company has established an environmental management system, successfully implementing measures that resulted in no environmental pollution incidents or administrative penalties in 2024[183]. - The company actively engages in community support, donating items for waste classification and books to enhance cultural life[182]. - The company has implemented carbon reduction measures, successfully reducing carbon dioxide equivalent emissions by 108 tons[177]. - The company has been involved in various poverty alleviation and rural revitalization projects, with total investments of RMB 1.3 million in charitable donations and sponsorships[187]. Shareholder Relations - The company has a cash dividend policy, distributing at least 30% of the distributable profits as cash dividends annually, subject to certain conditions[153]. - The company has established a mechanism for independent directors to review and provide opinions on profit distribution proposals[157]. - The company has a differentiated cash dividend policy, ensuring dividends are distributed when there are no significant investment plans or cash expenditures[153]. - The company confirmed the salary standards for senior management for 2024 and established performance assessment plans for the same year[145]. - The company emphasizes a broadband salary concept, linking employee compensation to job value and individual capability[149].

Financial Performance - The company's operating revenue for Q1 2025 was RMB 61,792,980.19, a decrease of 12.11% compared to RMB 70,304,397.74 in the same period last year[4]. - Net profit attributable to shareholders was RMB 10,901,715.10, a significant turnaround from a loss of RMB 3,719,366.81 in the previous year[4]. - The net profit after deducting non-recurring gains and losses was RMB 9,199,267.30, compared to a loss of RMB 5,290,448.88 last year, marking a substantial improvement[4]. - The basic earnings per share increased to RMB 0.02 from a loss of RMB 0.01 in the same period last year, reflecting a 300% increase[4]. - Operating profit for Q1 2025 was ¥20,928,778.23, a significant improvement from a loss of ¥5,513,186.84 in Q1 2024[22]. - Net profit for Q1 2025 reached ¥17,937,326.16, compared to a net loss of ¥4,361,103.22 in Q1 2024[22]. - Basic earnings per share for Q1 2025 was ¥0.02, recovering from a loss of ¥0.01 in Q1 2024[23]. Assets and Liabilities - Total assets at the end of the reporting period were RMB 1,833,322,547.46, a slight increase of 0.35% from RMB 1,826,839,219.54 at the end of the previous year[5]. - The total assets as of March 31, 2025, amounted to CNY 1,833,322,547.46, a slight increase from CNY 1,826,839,219.54 on December 31, 2024[17]. - The company reported a total of CNY 678,355,838.27 in current assets, down from CNY 691,774,180.51, indicating a decrease of about 1.9%[17]. - The total liabilities decreased to CNY 106,521,032.35 from CNY 123,645,731.78, representing a reduction of about 13.9%[19]. - The equity attributable to shareholders increased to CNY 1,577,050,799.05 from CNY 1,560,478,382.76, showing an increase of approximately 1.1%[19]. Cash Flow - The net cash flow from operating activities was negative at RMB -5,599,908.01, worsening from RMB -1,229,734.74 in the previous year[4]. - Cash flow from operating activities in Q1 2025 was negative at -¥5,599,908.01, compared to -¥1,229,734.74 in Q1 2024[25]. - Cash flow from investing activities generated ¥20,094,616.04 in Q1 2025, contrasting with a negative cash flow of -¥68,810,882.78 in Q1 2024[25]. - Cash and cash equivalents at the end of Q1 2025 totaled ¥362,240,931.99, up from ¥56,618,265.57 at the end of Q1 2024[26]. Investments and Acquisitions - The company completed the acquisition of 70% of Guizhou Lucheng Biological Technology Co., Ltd. for RMB 22.4 million, enhancing its capabilities in the in vitro diagnostic materials sector[14]. - The company’s long-term investments in fixed assets rose to CNY 29,844,251.25 from CNY 29,045,175.02, an increase of approximately 2.7%[18]. - The company reported a significant increase of 88.05% in net profit after deducting non-recurring gains and losses, amounting to RMB 11,710,828.55 when excluding stock incentive expenses[5]. Cost Management - Total operating costs for Q1 2025 were ¥41,355,751.57, down 48% from ¥79,483,781.34 in Q1 2024[22]. - The company reported a significant reduction in management expenses, from ¥21,100,810.08 in Q1 2024 to ¥11,291,949.78 in Q1 2025, a decrease of approximately 46.6%[22]. Other Financial Metrics - The weighted average return on net assets rose to 0.70%, an increase of 1 percentage point from -0.30% last year[5]. - The company completed the cancellation of 2,237,800 restricted shares, reducing the total number of restricted shares to 6,682,500[16]. - The company achieved a net investment income of ¥284,477.72 in Q1 2025, down from ¥857,854.31 in Q1 2024[22].

海利生物（603718）公告，2024年营业收入2.71亿元，同比增长12.59%。归属于上市公司股东的净利润 1.71亿元，同比增长172.28%。基本每股收益0.27元／股，同比增长170.00%。向全体股东每10股派发现 金红利0.784元(含税)。 ...

海利生物（603718）公告，2025年第一季度营收为6179.3万元，同比下降12.11%；净利润为1090.17万 元，去年同期净亏损371.94万元。 ...

证券代码：603718 证券简称：海利生物 公告编号：2025－018 上海海利生物技术股份有限公司 关于完成工商变更登记的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 上海海利生物技术股份有限公司（以下简称"公司"）于 2025 年 1 月 22 日 召开第五届董事会第十二次会议和第五届监事会第六次会议，审议通过了《关于 2023 年限制性股票与股票期权激励计划部分限制性股票回购注销与部分股票期 权注销的议案》《关于变更公司注册资本并修订<公司章程>的议案》，拟变更注册 资本同时对现行《公司章程》相关条款进行修订。公司回购注销的限制性股票数 量合计为 2,237,800 股，上述注销事项完成后，公司股份总数将由 657,900,000 股 变更为 655,662,200 股，注册资本将由 657,900,000 元变更为 655,662,200 元。 近日公司完成了营业执照的工商变更登记手续和公司章程的备案工作，领取 了上海市市场监督管理局换发的《营业执照》。公司《营业执照》登记信息具体 如下： 名 称：上海海 ...

证券代码：603718 证券简称：海利生物 公告编号：2025-017 上海海利生物技术股份有限公司 关于持股 5%以上股东权益变动触及 1%整倍数 的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 公司于 2025 年 4 月 16 日收到作为合计持股 5%以上股东的方章乐先生发来的 《关于权益变动触及 1%整倍数的告知函》，获悉在 2025 年 4 月 15 日，方章乐先生 通过大宗交易的方式减持公司无限售流通股 8,291,600 股,占公司总股本的 1.26%， 权益变动触及 1%的整倍数（即 8%）。具体如下： 一、本次权益变动基本情况 1、信息披露义务人基本信息 方章乐，男，中国国籍，无其他国家或地区的居留权，身份证号码为 3301241994****19，1994 年生，住所和通讯地址为杭州市下城区**公寓*幢*单元* 室。 2、权益变动明细情况 | | | 方文艳、方章乐作为一致行动人为上海海利生物技术股份有限公司（以下简称 "公司"）持股 5%以上的大股东，本次权益变动为其中 ...

证券代码：603718 证券简称：海利生物 公告编号：2025－016 关于 2023 年限制性股票与股票期权激励计划 部分限制性股票回购注销完成的公告 上海海利生物技术股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、本次限制性股票回购注销的决策与信息披露 2025年4月9日，公司披露了《上海海利生物技术股份有限公司关于2023 年限制性股票与股票期权激励计划部分限制性股票回购注销实施公告》（公 告编号：2025-015号）。 二、本次限制性股票回购注销实施情况 近日，公司收到了中国证券登记结算有限责任公司上海分公司出具的《 证券变更登记证明》，本次回购注销的限制性股票已过户至公司开立的回购 专用证券账户，并于2025年4月11日完成注销。公司后续将依法办理相关工商 变更登记手续。 2025年1月22日，公司召开第五届董事会第十二次会议和第五届监事会第 六次会议，审议通过了《关于2023年限制性股票与股票期权激励计划限制性 股票第一个解除限售期解除限售条件成就的议案》《关于调整2023年限制性 股票与股票期权 ...

Core Insights - The global animal vaccine market is projected to exceed $14 billion in 2024, following a market size of over $13.5 billion in 2023, with a compound annual growth rate (CAGR) of 10.10% over the past five years [1][8]. Market Overview - Animal vaccines, also known as veterinary vaccines, are products made from pathogenic microorganisms that stimulate the immune system of animals to produce specific antibodies, thereby preventing infectious diseases [1]. - North America, including the United States and Canada, is the largest regional market for animal vaccines, accounting for approximately 45% of the global market share in 2023 [3]. Industry Competition - Leading companies in the global animal vaccine industry offer a diverse range of products, including vaccines for pets, pigs, poultry, ruminants, and aquaculture [5]. - Major players such as Merck Animal Health, Zoetis, and Boehringer Ingelheim have established multiple production bases worldwide, indicating significant production capacity [5]. Company Profiles - **Merck Animal Health**: Offers pet vaccines, pig vaccines, poultry vaccines, and aquaculture vaccines, with 29 production bases across 12 countries, including a major facility in Suzhou, China [6]. - **Zoetis**: Operates production bases in the United States and China, having established its first R&D and production base in China in 2019 [6]. - **Boehringer Ingelheim**: Maintains over 20 production bases globally, with two facilities located in Nanchang and Taizhou, China [6]. - **Hualan Biological Engineering**: Initially focused on blood products, it has become a major producer of influenza vaccines in China, accounting for over 40% of the national market [6]. - **Fubao Animal Health**: Produces vaccines for pigs, poultry, and aquaculture, with production bases in the United States and Suzhou, China [6].

上海海利生物技术股份有限公司 关于 2023 年限制性股票与股票期权激励计划 部分限制性股票回购注销实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 回购注销原因：上海海利生物技术股份有限公司（以下简称"公司"） 于2025年1月22日召开第五届董事会第十二次会议及第五届监事会第六次 会议，审议通过了《关于2023年限制性股票与股票期权激励计划部分限 制性股票回购注销与部分股票期权注销的议案》。根据《上市公司股权 激励管理办法》（以下简称"《管理办法》"）、《上海海利生物技术股 份有限公司2023年限制性股票与股票期权激励计划（草案）》（以下简 称"《激励计划》"）的相关规定，鉴于公司2023年限制性股票与股票 期权激励计划（以下简称"本次激励计划"）获授限制性股票的激励对 象中有10人离职、16人因所属子公司从公司剥离不再为公司控股子公司 、1人担任公司监事，从而均不具有参与本次激励计划的主体资格，同意 对前述激励对象已获授但尚未解除限售的175万股限制性股票予以回购注 销。同时根据《激励计划》《上海 ...

证券代码：603718 证券简称：海利生物 公告编号：2025－014 上海海利生物技术股份有限公司 关于控股子公司医疗器械生产许可证变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 上海海利生物技术股份有限公司（以下简称"公司"）控股子公司陕西瑞盛生 物科技有限公司（以下简称"瑞盛生物"）于近日收到陕西省药品监督管理局换发 的《医疗器械生产许可证》，本次变更系生产地址的新增，生产地址在原有的基础 上增加"陕西省西安市经开区泾渭新城泾渭中小工业园 A5 厂房北半栋"。变更后 的具体情况如下： 一、《医疗器械生产许可证》基本情况 许可证编号：陕食药监械生产许 20190037 号 统一社会信用代码：916100006715226433 企业名称：陕西瑞盛生物科技有限公司 住所：陕西省西安市经开区泾渭新城泾渭中小工业园 2 号楼南半栋 生产地址：陕西省西安市经开区泾渭新城泾渭中小工业园 2 号楼南半栋；陕 西省西安市经开区泾渭新城泾渭中小工业园 A5 厂房北半栋 植入及组织重建材料；*** 发证部门：陕西省药品监督 ...